S&P Futures
4,533.25 -42.50 (-0.93%) Dow Futures
34,559.00 -63.00 (-0.18%) Nasdaq Futures
15,687.50 -301.00 (-1.88%) Russell 2000 Futures
2,156.20 -49.00 (-2.22%) Crude Oil
66.22 -0.28 (-0.42%) Gold
1,782.10 +21.40 (+1.22%)
Cue Health Inc. (HLTH)
- PR Newswire
Cue Health Receives Singapore HSA Authorization for its Molecular COVID-19 Test for Self-Testing
Cue Health ("Cue") (Nasdaq: HLTH), a healthcare technology company, today announced it received Pandemic Special Access Route (PSAR) authorization from the Health Sciences Authority (HSA) for the Cue COVID-19 Test for self-testing in Singapore. The Cue COVID-19 Test is the first natively digital molecular diagnostic product ever authorized for consumer home use in Singapore. Cue's partnership with Omnicell Pte Ltd allows Cue to immediately begin supporting public sector use of the Cue COVID-19 T
- PR Newswire
Cue Health Confirms COVID-19 Tests Can Detect Omicron Variant
Cue Health ("Cue") (Nasdaq: HLTH), a healthcare technology company, today announced it has completed an analysis of the SARS-CoV-2 B.1.1.529 variant, designated by the World Health Organization as Omicron. Using information from the GISAID database, Cue has determined its COVID-19 tests, which uses molecular (NAAT) technology, can detect the Omicron variant. Specifically, Cue found that 99.2% of the available 127 published sequences are a perfect match to the primers used in the Company's tests.
- PR Newswire
Helix and Cue Health Collaborate to Provide Individuals with Access to their COVID-19 Variant Sequencing Information
Helix, a leading genomics company that provides nationwide viral surveillance of respiratory disease, and Cue Health Inc. (Nasdaq: HLTH), a healthcare technology company, announced a new collaboration today to provide individuals who test positive on Cue's at-home molecular COVID-19 test the opportunity to learn which variant they have contracted as part of a broader research study on the SARS-CoV-2 virus.
